For HbA1c in RA Patients, Sarilumab Outperforms Adalimumab, Placebo
A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.
Read More
Baricitinib Hits 16-Week Marks for Atopic Dermatitis
The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.